RegulatoryOfficial

European Commission authorises Alexion's Klygefa (gefurulimab) in new marketing authorisation

🇪🇺 European Commission (Union Register) · Thu 12 Nov 2026

Commission Decision (2026) 8207 of 12 November 2026 grants Alexion Europe SAS a marketing authorisation for Klygefa, following EMA procedure EMEA/H/C/006558/0000.

The European Commission has granted a new marketing authorisation for Klygefa (gefurulimab), held by Alexion Europe SAS. The decision, Commission Decision (2026) 8207, is dated 12 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: European Commission (Union Register) ↗

Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.